TY - JOUR T1 - Evaluation of the Swedish adjustable gastric band VC (SAGB-VC) in an Australian population: early results JF - Canadian Journal of Surgery JO - CAN J SURG SP - 15 LP - 20 DO - 10.1503/cjs.011511 VL - 56 IS - 1 AU - Jennifer B. Keogh AU - Anthony Brancatisano AU - Sue F. Taylor AU - Fiona McDonald AU - Roy Brancatisano AU - Jeffrey M. Hamdorf AU - Jacob Chisholm AU - Lillian Kow AU - Sara Wahlroos AU - Brendan Ryan AU - Jim Toouli Y1 - 2013/02/01 UR - http://canjsurg.ca/content/56/1/15.abstract N2 - Background: The Swedish adjustable gastric band VC (SAGB-VC) has been in use in Australia since 2007. We evaluated its efficacy and safety.Methods: We retrospectively analyzed the prospective clinical data of patients who received the implant between November 2007 and June 2009 at 3 Australian bariatric centres.Results: In all, 1176 patients (mean age 45.9 [standard deviation (SD) 12.3] yr, mean body mass index 43.4 [SD 7.6]) received the SAGB-VC. At a mean follow-up of 11 (SD 3) months, weight reduced by a mean of 18.4 (SD 11.1) kg with an excess weight loss of 37.8% (SD 19.9%). Body mass index decreased (from mean 43.4 [SD 7.7] to mean 36.7 [SD 6.5], p < 0.001). Type 2 diabetes (T2DM) was reported in 167 patients and hypertension in 373. Improvement occurred in 73.5% of patients with T2DM and 31% with hypertension, with patient-reported reduction or cessation of medication. Metabolic syndrome indices improved during follow-up: high-density lipoprotein cholesterol (mean 1.3 [SD 0.3] v. mean 1.4 [SD 0.3] mmol/L, p < 0.001), triglycerides (mean 1.6 [SD 0.8] v. mean 1.3 [SD 0.7] mmol/L, p < 0.001), waist circumference (men 141 [SD 103] to 121 [SD 15] cm, women 117 [SD 14] to 105 [SD 14] cm, both p < 0.001), C-reactive protein (90.5 [SD 75.2] v. 53.3 [SD 61.9] nmol/L, p < 0.001). The complication rate was 4.2%.Conclusion: The SAGB-VC is safe and effective for treating obesity and its comorbidities. The results are reproducible in separate Australian centres and consistent with published literature. ER -